
Tempus is a technology company leading the adoption of #AI to advance precision medicine.
Chicago, IL
Joined October 2015
- Tweets1.5K
- Following1.1K
- Followers15.4K
- Likes2.1K
Applications are now open for The PRECISION Challenge, a national program opening our foundation model work to the broader research community, including computational biologists, bioinformaticians, biostatisticians, and data scientists.
The PRECISION Challenge will provide selected participants with an unprecedented ecosystem of resources, combining direct financial funding with scientific and analytical infrastructure. Program recipients will gain structured access to our proprietary de-identified data library, alongside our suite of foundation models, agentic tooling, and compute capabilities in the Lens Workspaces environment.
Detailed eligibility requirements are provided with each RFP.
Apply now: tempus.co/4kkoHXW
xM (NeXT Personal® Dx) is a key part of the patient care continuum, providing crucial information during surveillance and monitoring for early-stage disease and for IO treatment response monitoring for late-stage disease.
Now available to support your clinical insights, Real-Time Variant Tracker™ is a supplemental part of xM (NeXT Personal® Dx) that tracks resistance and therapeutically targetable variants, including variants associated with NCCN guideline-recommended and FDA-approved therapies.
Learn more: tempus.co/4iLchFR
Tempus retweeted
What if AI could cut trial-matching chart review from 25 minutes to just 3 while boosting enrollment?
Join Chelsea Osterman, MD, next Wednesday at 12 PM ET to explore trial matching, EDC data transfer & automated tumor measurements.
Enroll > bit.ly/4xc9jQA
Our CEO and Founder @lefkofsky recently joined @MTSlive to discuss the evolving role of AI in clinical care as patients increasingly consult #GenAI tools with their own health data.
Over the next 3 to 5 years, healthcare systems must equip physicians with the same caliber of advanced, intelligent technology to support clinical decision-making.
Tempus AI CEO @lefkofsky predicts doctors will need access to the same AI tools as patients within the next 3-5 years.
People are already walking into appointments having uploaded their medical records to ChatGPT or Claude:
"Healthcare doesn’t really work in year-long denominations."
"Over the next maybe 3 to 5 years, the US healthcare system will have to arm physicians with the same kind of technologies that patients are armed with because there's an imbalance now."
"People are walking in, they've uploaded their medical records to Chat or to Claude, and so there's an imbalance."
"Over the longer term, you'll start to bring some of the benefits of AI to drug development. But it isn't one year out."
@TempusAI
Next week, Tempus will present six abstracts, including three oral presentations, at the Connective Tissue Oncology Society Annual Meeting (November 18–21).
In rare diseases like sarcoma, small patient populations have historically created barriers to research. By leveraging our multimodal library, which includes real-world data from more than 45,000 patients across 615 rare and ultra-rare cancer types, our team is uncovering novel insights into rare mesenchymal tumors to advance precision oncology.
Read the full announcement to learn more: tempus.co/4zKUQww #CTOS2026

ALT Announcement for the 2026 Connective Tissue Oncology Society Annual Meeting in Seoul, South Korea, from November 18-21, 2026. It highlights Tempus presenting six abstracts on advances in molecular diagnosis and treatment options. The background features a blurred image of a person working at a computer with blue digital graphics.
Lung cancer demands clarity at every stage—because every patient’s journey is unique.
This #LungCancerAwarenessMonth, we honor the resilience of the lung cancer community. Tempus is proud to support patients and their care teams with comprehensive genomic profiling, guiding personalized treatment decisions from initial diagnosis to long-term monitoring.
Learn more about our comprehensive portfolio for lung cancer patients: tempus.co/4sSoduh
Tempus retweeted
We can't wait to see you this week at #NSGC26!
Visit Booth 1169 to explore how we’re delivering true diagnostic intelligence—from our comprehensive testing compendium and vast, representative databases driving equity at scale, to seamless EHR integration paired with lab-driven reanalysis.
Find more information, including a list of our scientific posters here: hubs.ly/Q04DPD780
#ScientificSessions26: @BrandonFornwalt will join fellow @ARPA_H ADVOCATE awardees on stage to discuss how they are building AI-clinician extenders designed to expand access to cardiology expertise for heart failure patients.
Learn more: tempus.co/4kB4FbB
#AHA26
Data professionals spend as much as 40% of their time searching for data rather than analyzing it. Tempus One now surfaces data model definitions, schema, and analytic best practices for faster analyses with fidelity.
Learn more in a new article here: tempus.co/4inmwkV
We're looking forward to next week's #AMP2026. Our team will be on-site showcasing our comprehensive genomic testing portfolio alongside our latest AI-powered digital pathology applications.
Visit Booth #909 or attend our workshop on Nov. 11 to learn more.
tempus.co/4BI2cSJ
Listen in as our CEO and founder @lefkofsky recaps Q3 at Tempus ⬇️
Access the Q3 shareholder letter here: tempus.co/4zmfIdj
Tempus is a technology company making precision medicine a reality through the practical application of artificial intelligence in healthcare.
By continuously transforming data into insights, Tempus is building a learning healthcare ecosystem in which every patient can benefit from the treatment and experiences of those who came before.
Learn more: tempus.co/4knQbvA
This #BreastCancerAwarenessMonth, we recognize the millions of patients, families, and care teams navigating the complexities of breast cancer.
Because no two journeys are the same, timely genomic insights are critical for guiding targeted therapies. Tempus xF+ delivers broad-panel liquid biopsy profiling from a single blood draw to detect ESR1 and other actionable alterations at progression or when tissue is limited. Now, that same sample provides rapid pharmacogenomic (PGx) insights for DPYD and UGT1A1 in just ~3–5 days—helping evaluate toxicity risks and guide dosing without needing an extra draw.
Learn more about how xF+ supports personalized care decisions: tempus.co/3VZftWX
We're onsite at #AMCPNexus sharing how real-world evidence can be leveraged to advance managed care pharmacy practice. Attend tomorrow's live session to hear Emilie Scherrer expand on findings from her abstract presentation, which suggest that the composite mortality variable is a reliable endpoint for real-world evidence analyses.
More info: tempus.co/amcpnexus
Attend tomorrow's live session at #ResearchRevolution to hear from industry experts on how AI, operational redesign, and smarter ways of working are enabling just-in-time trial execution. Panelists will discuss what tools are improving speed and predictability, including Tempus Next, designed to accelerate clinical trial enrollment with AI-enabled pre-screening, integrated workflows and performance tracking.
Learn more: tempus.co/4iHVIM8
Our xR assay has received certification under the European Union’s In Vitro Diagnostic Regulation (IVDR) as a Class C in vitro diagnostic device.
xR detects gene rearrangements and specific splice variants in solid tumor tissue to support clinical management. This achievement furthers our work to expand access to our advanced RNA sequencing tools for healthcare providers, biopharma partners and cancer patients.
Read on: tempus.co/4smWpOg
Our team is on-site at #ESMO26 sharing new product offerings designed to advance drug discovery and development.
Visit us at Booths #1068 & 1069 to explore how our proprietary foundation models enable rapid AI application development and meaningful insights across the end-to-end drug development lifecycle, from discovery to clinical development and commercialization.
Learn more about our foundation models: tempus.co/4ih8Tm8
Today we announced a strategic collaboration with @bmsnews to support their oncology drug portfolio.
We also announced a strategic collaboration with Bristol Myers Squibb and @pathos to advance drug discovery in Alzheimer’s disease.
Collectively, this makes BMS one of our largest data and modeling customers. Through this collaboration, BMS researchers will be able to train advanced AI models using de-identified data to surface breakthroughs and increase the probability of success when developing therapies for both cancer patients and those suffering from Alzheimer’s disease.
Read on: pathos.com/pathos-ai-announc… & tempus.com/news/pr/tempus-ex…
















